Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Deferred Revenue (2018 - 2025)

Regenxbio (RGNX) has 11 years of Current Deferred Revenue data on record, last reported at $10.5 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 8988.7% year-over-year to $10.5 million; the TTM value through Dec 2025 reached $10.5 million, up 8988.7%, while the annual FY2025 figure was $10.5 million, 8988.7% up from the prior year.
  • Current Deferred Revenue reached $10.5 million in Q4 2025 per RGNX's latest filing, down from $13.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $39.9 million in Q1 2025 and bottomed at $13000.0 in Q1 2024.
  • Average Current Deferred Revenue over 5 years is $6.7 million, with a median of $2.6 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: crashed 99.01% in 2024, then surged 306707.69% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.3 million in 2021, then tumbled by 45.12% to $1.8 million in 2022, then plummeted by 91.91% to $148000.0 in 2023, then decreased by 22.3% to $115000.0 in 2024, then soared by 8988.7% to $10.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $10.5 million in Q4 2025, $13.2 million in Q3 2025, and $37.8 million in Q2 2025.